- Home
- ACIU vs SOPH Comparison
ACIU vs SOPH Comparison
Compare ACIU & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- SOPH
- Stock Information
- Founded
- ACIU 2003
- SOPH 2011
- Country
- ACIU Switzerland
- SOPH Switzerland
- Employees
- ACIU N/A
- SOPH N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACIU Health Care
- SOPH Health Care
- Exchange
- ACIU Nasdaq
- SOPH Nasdaq
- Market Cap
- ACIU 213.3M
- SOPH 231.8M
- IPO Year
- ACIU 2016
- SOPH 2021
- Fundamental
- Price
- ACIU $2.48
- SOPH $3.17
- Analyst Decision
- ACIU Strong Buy
- SOPH
- Analyst Count
- ACIU 2
- SOPH 0
- Target Price
- ACIU $10.00
- SOPH N/A
- AVG Volume (30 Days)
- ACIU 132.0K
- SOPH 39.6K
- Earning Date
- ACIU 11-04-2025
- SOPH 11-04-2025
- Dividend Yield
- ACIU N/A
- SOPH N/A
- EPS Growth
- ACIU N/A
- SOPH N/A
- EPS
- ACIU N/A
- SOPH N/A
- Revenue
- ACIU $36,362,036.00
- SOPH $69,688,000.00
- Revenue This Year
- ACIU N/A
- SOPH $16.60
- Revenue Next Year
- ACIU $1,022.98
- SOPH $18.77
- P/E Ratio
- ACIU N/A
- SOPH N/A
- Revenue Growth
- ACIU 86.71
- SOPH 7.32
- 52 Week Low
- ACIU $1.43
- SOPH $2.58
- 52 Week High
- ACIU $3.98
- SOPH $4.92
- Technical
- Relative Strength Index (RSI)
- ACIU 64.11
- SOPH 43.88
- Support Level
- ACIU $2.12
- SOPH $3.10
- Resistance Level
- ACIU $2.35
- SOPH $3.49
- Average True Range (ATR)
- ACIU 0.13
- SOPH 0.18
- MACD
- ACIU 0.04
- SOPH -0.03
- Stochastic Oscillator
- ACIU 95.74
- SOPH 12.35
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.